

IN THE CLAIMS:

Please add the following new claims.

--35. An isolated EDG receptor that upon activation results in increased induction of IL-8 or NF- $\kappa$ B, wherein said EDG receptor is a human EDG-4 receptor having the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 22, or a human EDG-4 receptor variant having an amino acid sequence which is at least 91% identical to SEQ ID NO: 17 or SEQ ID NO: 22, with the proviso that said human EDG-4 receptor variant is not a rat EDG receptor.

36. The isolated EDG receptor of claim 35, wherein said EDG receptor is activated by a lysolipid selected from one or more of the group consisting of lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P) and sphingosine phosphocholine (SPC).

37. The isolated EDG receptor of claim 35, wherein said EDG receptor has the amino acid sequence of SEQ ID NO: 17.

38. The isolated EDG receptor of claim 35, wherein said EDG receptor has the amino acid sequence of SEQ ID NO: 22.

39. An isolated EDG receptor that upon activation results in increased induction of IL-8 or NF- $\kappa$ B, wherein said EDG receptor is a human EDG-4 receptor having the

amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 22, or a human EDG-4 receptor variant having an amino acid sequence which is at least 91% identical to SEQ ID NO: 17 or SEQ ID NO: 22, with the proviso that said human EDG-4 receptor variant has an amino acid other than phenylalanine at position 273 according to Figure 17B.

40. The isolated EDG receptor of claim 39, wherein said EDG receptor is activated by a lysolipid selected from one or more of the group consisting of lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P) and sphingosine phosphocholine (SPC).

41. An isolated EDG receptor that upon activation results in increased induction of IL-8 or NF- $\kappa$ B, wherein said EDG receptor is a human EDG-4 receptor having the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 22, or a human EDG-4 receptor variant having an amino acid sequence which is at least 99% identical to SEQ ID NO: 17 or SEQ ID NO: 22.

42. The isolated EDG receptor of claim 41, wherein said EDG receptor is activated by a lysolipid selected from one or more of the group consisting of lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P) and sphingosine phosphocholine (SPC).


*A*  
43. The isolated EDG receptor of claim 41, wherein said human EDG-4 receptor variant has an amino acid other than phenylalanine at position 273 according to Figure 17B.--

#### REMARKS

In this amendment, applicants amend the specification by inserting a Sequence Listing as new pages 1-16 at the end of the application and by labeling the sequences in the specification consistent with the Sequence Listing.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300.

Respectfully submitted,

*for*   
Richard J. Berman  
Registration No. 39,107 #2290

Customer No. 004372  
AREN'T FOX KINTNER PLOTKIN & KAHN, PLLC  
1050 Connecticut Avenue, N.W.,  
Suite 400  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000  
Fax: (202) 638-4810